genital%20herpes
GENITAL HERPES
Genital herpes is a recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV).
HSV-2 is usually the cause but HSV-1 may occur in up to 1/3 of new cases.
HSV-1 tends to cause fewer recurrences & milder disease than HSV-2.
The incubation period is 2 days-2 weeks after exposure.

Genital%20herpes Treatment

Pharmacotherapy

  • Use is warranted in suspected or diagnosed initial genital herpes infection with lesions not yet fully crusted
    • To be administered within 5 days of the start of infection and continued until new lesions are forming or if there is persistence of systemic symptoms
    • Treatment within 1 day of lesion onset may end development of lesions
  • Antivirals are effective in reducing severity and duration of symptoms
    • Neither can eliminate the virus nor affect the risk and natural course of genital herpes infection
  • Oral antivirals are more effective than topical agents in the management of the initial episode
  • Choice of agent depends on cost, dosing schedule and patient preference
    • Oral Aciclovir, Famciclovir, and Valaciclovir have similar efficacy

Aciclovir (Oral, IV)

  • Acyclic purine nucleoside analogue that is a competitive inhibitor of viral DNA polymerase
  • Limits viral replication and stops further spread of the virus to other cells
  • Oral and IV are both effective in treating HSV-1 and HSV-2
  • IV is usually reserved for severe disease or complications where hospitalization is necessary
  • Topical agent has limited efficacy, hence not recommended
  • Bioavailability is poor requiring frequent dosing

Famciclovir (Oral)

  • Famciclovir is a pro-drug of Penciclovir
  • Has higher bioavailability than Penciclovir and is rapidly converted to Penciclovir in GIT, blood and liver
  • Penciclovir has similar mechanism of action as Aciclovir

Valaciclovir (Oral)

  • L-valine ester pro-drug of Aciclovir, rapidly metabolized to Aciclovir by liver and intestine
  • Has better absorption after oral administration than Aciclovir making lower doses or lesser dosing frequency possible
  • Has been shown to decrease risk of transmission
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.